经济观察网 浩希健康科技（HAO.us）近期发布了最新财报，显示其营业收入为3280万美元，净利润为 388万美元，每股收益1.66美元，市盈率为0.81倍。 业绩经营情况 根据最新披露的财报数据，公司营业收入为32.80百万美元，净利润为3.88百万美元，每股收益1.66美 元，市盈率为0.81倍。这些数据反映了公司近期的经营表现。 行业政策与环境 公司业务高度依赖在线广告营销行业，尤其是医疗保健领域的数字广告趋势。近期行业整体波动较大， 例如广告营销板块出现下跌，可能影响公司股价。此外，医疗AI应用等技术发展可能间接波及公司业 务。 以上内容基于公开资料整理，不构成投资建议。 ...

公告编号:2026-003 （来源：财闻） 标的公司是中国医疗卫生信息互联互通技术联盟暨HL7 China的会员单位，是中部地区首家通过FHIR Connectathon 13项系统测试的医疗信息化企业。 2月5日，健麾信息（605186.SH）公告称，公司拟以3768.75万元、2285.63万元、637.50万元、679.14万 元分别收购周校平、泽朴投资、博科医信、博科国信持有的博科国信（武汉）科技有限公司16.75%、 13.25%、4.00%、4.00%股权。交易完成后，健麾信息将持有标的公司70%的股权。 标的公司是中国医疗卫生信息互联互通技术联盟暨HL7 China的会员单位，是中部地区首家通过FHIR Connectathon 13项系统测试的医疗信息化企业。标的公司在医疗AI应用（如B-Klinik智能体）方面的研 发积累，将为公司核心业务注入智能化创新动能，有助于开拓在智慧医院、县域医共体及数智康养等领 域的业务机会。 证券代码:605186 证券简称:健磨信息 ● 交易简要内容 上海健麾信息技术股份有限公司(以下简称"公司"或"健磨信息") 拟以人民币 3,768.75 万元、2,285 ...

健麾信息(605186.SH)公告称，公司拟以3768.75万元、2285.63万元、637.50万元、679.14万元分别收购 周校平、泽朴投资、博科医信、博科国信持有的博科国信（武汉）科技有限公司16.75%、13.25%、 4.00%、4.00%股权。交易完成后，健麾信息将持有标的公司70%的股权。标的公司是中国医疗卫生信息 互联互通技术联盟暨HL7 China的会员单位，是中部地区首家通过FHIR Connectathon 13项系统测试的医 疗信息化企业。标的公司在医疗AI应用（如B-Klinik智能体）方面的研发积累，将为公司核心业务注入 智能化创新动能，有助于开拓在智慧医院、县域医共体及数智康养等领域的业务机会。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

每经AI快讯，2月5日，健麾信息（605186）(605186.SH)公告称，公司拟以3768.75万元、2285.63万元、 637.50万元、679.14万元分别收购周校平、泽朴投资、博科医信、博科国信持有的博科国信(武汉)科技 有限公司16.75%、13.25%、4.00%、4.00%股权。交易完成后，健麾信息将持有标的公司70%的股权。 标的公司是中国医疗卫生信息互联互通技术联盟暨HL7China的会员单位，是中部地区首家通过FHIR Connectathon13项系统测试的医疗信息化企业。标的公司在医疗AI应用(如B-Klinik智能体)方面的研发积 累，将为公司核心业务注入智能化创新动能，有助于开拓在智慧医院、县域医共体及数智康养等领域的 业务机会。 ...

Core Viewpoint - The healthcare service industry, traditionally considered "counter-cyclical," is facing pressure due to fluctuating consumer confidence and stringent cost-control policies, leading to profit compression for many medical institutions. However, Zhuozheng Medical, a leading private healthcare brand, shows a contrasting growth trajectory with significant revenue and profit increases projected from 2022 to 2024 [1]. Group 1: Financial Performance - Zhuozheng Medical's revenue is projected to grow from 470 million yuan in 2022 to 960 million yuan in 2024, representing a compound annual growth rate (CAGR) of 42.2% [1]. - The company's gross profit is expected to rise from 43.98 million yuan in 2022 to 230 million yuan in 2024, with a CAGR of 126.7% [1]. - The net profit is forecasted to turn positive in 2024, with figures of -220 million yuan, -350 million yuan, and 80.23 million yuan for the years 2022, 2023, and 2024 respectively, leading to a net profit margin of 8.4% in 2024 [1]. Group 2: Business Model - Zhuozheng Medical does not rely on medical insurance, with only 0.2% of its revenue coming from national medical insurance in 2022 and 2023, and 1.2% in 2024, primarily from a newly acquired hospital [2]. - The company generates over 85% of its revenue from cash payments, allowing for self-pricing and avoiding over-treatment revenue models [3]. - The focus on cash-paying customers has enabled Zhuozheng Medical to maintain positive operating cash flow, exceeding 1 billion yuan in the first eight months of 2025 [3]. Group 3: Customer Acquisition Strategy - Zhuozheng Medical adopts a "slow and steady" approach, relying on word-of-mouth and customer referrals rather than aggressive marketing, with marketing expenses constituting only 2.7%, 1.2%, and 1.7% of revenue from 2022 to 2024 [5]. - The company has a high customer retention rate, with membership renewal rates increasing from 42% in 2022 to 67% in 2025, and patient return rates rising from 75.7% to 82.7% over the same period [6][8]. Group 4: Service Model - Zhuozheng Medical employs a "family multi-specialty" model, addressing common health issues and extending care across various specialties, which increases customer retention and frequency of visits [12]. - In 2024, the average customer visited Zhuozheng Medical nearly four times, significantly higher than typical single-specialty institutions [13]. Group 5: Technology Integration - The company has integrated AI into its operations since 2020, focusing on practical applications rather than following industry trends, which has led to a reduction in labor costs from 80% to 54% of revenue by 2025 [14]. - AI applications have improved operational efficiency, such as automating patient appointment assessments and enhancing diagnostic processes [14]. Group 6: Market Outlook - The private mid-to-high-end healthcare service market in China is projected to grow from 426.4 billion yuan in 2024 to 831.4 billion yuan by 2029, with a CAGR of 14.3%, indicating strong potential for companies like Zhuozheng Medical [16].

Core Insights - Hong Kong has established the Von Neumann Institute to integrate embodied intelligence, generative AI, and advanced supercomputing technologies, aiming to promote interdisciplinary collaboration and commercialize research outcomes [1][2] - The institute focuses on five key AI areas: multimodal AI systems, enhancing AI reasoning capabilities, robotics intelligence, AI-driven 3D understanding, and healthcare service reform through large models [2][3] - The institute aims to build a talent pipeline in AI through educational initiatives, targeting over 100 PhD students and engaging with local schools to foster innovation [3] Group 1 - The Von Neumann Institute is the first "full-chain practical" AI research institute in the Greater Bay Area, bridging basic research and industrial application [2] - The institute's approach includes establishing specialized laboratories and joint industry-university collaborations to accelerate the transition from theoretical research to product development [2][3] - The leadership of Jia Jiaya, who has experience as a scientist, entrepreneur, and educator, positions the institute to become a model of "top-tier research and grounded industry" [3] Group 2 - Jia Jiaya emphasizes Hong Kong's role as an "innovation brain" due to its international capital flow, top-tier research resources, and global talent hub, while Shenzhen acts as the "industrial driver" [4] - The integration of large models and visual sensor hardware by Simo Technology showcases a demand-driven approach to innovation, with applications in major factories like Tesla and BYD [4][5] - The collaboration between Hong Kong and Shenzhen has created a rapid coordination mechanism, allowing for quick transitions from research to production [5]